Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NADALS Basket Proof of Concept Trial Using Baricitinib
NCT05189106Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2022
- Primary completion
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of baricitinib in Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Mild Cognitive Impairment (MCI), subjective cognitive decline (SCD), sponsored by Massachusetts General Hospital. Started Dec 2022; status: completed.
02
Drugs
baricitinib
03
Conditions
Alzheimer's disease (AD)amyotrophic lateral sclerosis (ALS)Mild Cognitive Impairment (MCI)subjective cognitive decline (SCD)
Beyond the preview
Go deeper on NCT05189106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05189106.